FGL1 Inhibitors
Chemical inhibitors of FGL1 can be categorized based on their mechanism of action, specifically targeting signaling pathways that are known to influence the function of FGL1. Suramin is a complex molecule that impedes the activity of various growth factors. The relevance to FGL1 inhibition lies in the protein's role in immune regulation; by blocking growth factor pathways, Suramin can attenuate the effects of FGL1 on immune cells. This action is significant since growth factors can modulate immune responses wherein FGL1 is implicated.
Several inhibitors target the TGF-β signaling pathway, which is known to have a role in processes where FGL1 is involved, such as liver regeneration and fibrosis. Galunisertib, LY2109761, SB431542, GW788388, SD-208, A83-01, EW-7197, and LY2157299 (Galunisertib) all disrupt the TGF-β receptor kinase activity. This blockade results in diminishing the downstream signaling cascade that may otherwise regulate or enhance the activity of FGL1. For instance, Galunisertib, by inhibiting TGF-β receptor I kinase, can interfere with the signaling that potentially modulates FGL1 function. LY2109761 extends this effect by also inhibiting TGF-β receptor II kinase, providing a broader inhibition of the TGF-β pathway. The chemical Pirfenidone, with its anti-fibrotic characteristics, inhibits TGF-β, a cytokine involved in fibrogenesis, where FGL1 may play a role. This inhibition can reduce the fibrotic activity in which FGL1 is potentially involved, thereby functionally limiting FGL1's role in such processes. Halofuginone, on the other hand, prevents the phosphorylation of Smad3, a critical step in the TGF-β signaling pathway. By impeding this step, Halofuginone can reduce the regulatory effects that TGF-β signaling has on FGL1's activity, especially in fibrotic pathways. Lastly, RepSox inhibits ALK5 kinase activity within the TGF-β pathway, which is another potential route through which FGL1's function can be diminished, given the protein's putative regulation by or involvement in TGF-β mediated signaling.
| Product Name | CAS # | Catalog # | QUANTITY | Price | Citations | RATING |
|---|---|---|---|---|---|---|
Suramin sodium | 129-46-4 | sc-507209 sc-507209F sc-507209A sc-507209B sc-507209C sc-507209D sc-507209E | 50 mg 100 mg 250 mg 1 g 10 g 25 g 50 g | $152.00 $214.00 $728.00 $2601.00 $10965.00 $21838.00 $41096.00 | 5 | |
Suramin is a polysulfonated naphthylurea that inhibits various growth factors. FGL1 has been implicated in immune regulation and may interact with growth factor pathways. Suramin, by inhibiting these factors, could limit the functional effects of FGL1 on immune cells. | ||||||
LY2157299 | 700874-72-2 | sc-391123 sc-391123A | 5 mg 10 mg | $213.00 $359.00 | 3 | |
LY2157299 is a TGF-β receptor I kinase inhibitor. Since FGL1 is a hepatocyte-derived plasma protein that might be regulated by TGF-β signaling in some contexts, inhibition of this pathway by Galunisertib can lead to a functional reduction in FGL1 activity. | ||||||
SB 431542 | 301836-41-9 | sc-204265 sc-204265A sc-204265B | 1 mg 10 mg 25 mg | $82.00 $216.00 $416.00 | 48 | |
SB431542 selectively inhibits the TGF-β1 receptor ALK5, which is involved in TGF-β signaling. By inhibiting this receptor, SB431542 can reduce the functional activity of FGL1 if FGL1's activity is modulated by TGF-β signaling. | ||||||
GW788388 | 452342-67-5 | sc-363544 sc-363544A | 5 mg 25 mg | $95.00 $384.00 | ||
GW788388 is a new inhibitor of ALK5 and ALK4, which are receptors implicated in TGF-β signaling. By blocking these receptors, GW788388 can functionally inhibit FGL1 if its signaling or regulatory mechanisms involve TGF-β pathways. | ||||||
TGF-β RI Kinase Inhibitor V | 627536-09-8 | sc-203294 | 2 mg | $88.00 | 3 | |
SD-208 is a TGF-β receptor I kinase inhibitor, which could lead to functional inhibition of FGL1 if its activity is modulated by the TGF-β signaling that plays a part in liver disease mechanisms where FGL1 is active. | ||||||
A 83-01 | 909910-43-6 | sc-203791 sc-203791A | 10 mg 50 mg | $202.00 $811.00 | 16 | |
A83-01 is an inhibitor of TGF-β type I receptor ALK5 kinase, ALK4, and ALK7, which are all part of the TGF-β signaling pathway. Inhibition of this pathway can functionally inhibit FGL1 if it is regulated by or acts through TGF-β signaling. | ||||||
EW-7197 | 1352608-82-2 | sc-507465 | 5 mg | $345.00 | ||
EW-7197 is a potent ALK5 inhibitor, which can functionally inhibit FGL1 by disrupting the TGF-β signaling pathway, potentially affecting the regulatory mechanisms that control the expression or activity of FGL1. | ||||||
Pirfenidone | 53179-13-8 | sc-203663 sc-203663A | 10 mg 50 mg | $102.00 $416.00 | 6 | |
Pirfenidone has anti-fibrotic and anti-inflammatory properties and is known to inhibit TGF-β. By disrupting TGF-β signaling, Pirfenidone can functionally inhibit FGL1 if the protein's activity is associated with fibrotic processes. | ||||||
Halofuginone | 55837-20-2 | sc-507290 | 100 mg | $1775.00 | ||
Halofuginone is an inhibitor of the TGF-β signaling pathway, specifically by blocking Smad3 phosphorylation. This can functionally inhibit FGL1 by disrupting a pathway that may regulate or be influenced by FGL1 activity, such as in fibrogenesis. | ||||||
ALK5 Inhibitor II | 446859-33-2 | sc-221234 sc-221234A sc-221234B sc-221234C sc-221234D sc-221234E sc-221234F | 1 mg 5 mg 10 mg 50 mg 100 mg 500 mg 1 g | $77.00 $153.00 $219.00 $663.00 $1248.00 $4382.00 $7850.00 | 8 | |
RepSox is a selective inhibitor of the TGF-β type I receptor ALK5. By inhibiting ALK5, RepSox can functionally inhibit FGL1 if FGL1's activity is modulated by the TGF-β signaling pathway. | ||||||